New drug aims to silence harmful antibodies in kidney disease
NCT ID NCT07163611
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called obinutuzumab in 20 adults with a high-risk form of membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The goal is to see how quickly the drug lowers those harmful antibodies and whether it leads to remission. Participants receive two infusions initially, with possible extra doses after six months if needed, and are followed for a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- obinutuzumab (a monoclonal antibody drug)
- What this could lead to
- If successful, this could point toward a more effective treatment for high-risk membranous nephropathy, potentially leading to disease remission and preserved kidney function.
- What could go wrong
- This is a small, early pilot study with only 20 participants, so results may not apply to everyone. The drug may cause side effects, and not all patients may achieve remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY - PLA2R INDUCED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Nephrology, Radboud University Medical Center
RECRUITINGNijmegen, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a pill calm the immune attack on kidneys?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- Engineered immune cells take aim at autoimmune kidney diseases